Prostate cancer responds initially to hormonal manipulation by androgen withdrawal and peripheral androgen blockade. The inevitable progression to a hormone-refractory state is accompanied by an exacerbation of local symptoms and metastatic spread, principally to the bones, which has a considerable impact on quality of life and survival. Treatment of hormonerefractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases. Systemic treatments are not widely accepted in this setting, but clinical trials have demonstrated the potential for bone targeting agents such as strontium-89 and the bisphosphonates to palliate painful bone metastases and to delay progression in certain settings. Chemotherapy with mitozantrone in combination with steroids has previously been shown to have palliative benefits and to delay progression. The additional costs incurred by the use of chemotherapy or bone-targeting therapies may be offset by gains in overall care with fewer in-patient admissions compared with steroid monotherapy . Recent clinical trials have demonstrated that docetaxel significantly improves patient quality of life, and importantly, increases survival. Future studies investigating the timing of chemotherapy, combinations with existing treatments or other novel therapies are underway.
Introduction

Prostate cancer
Cancer of the prostate is the second most common cause of cancer death in men in Western countries today with over 200 000 deaths in the year 2000. 1 Many patients present with asymptomatic early-stage disease and have a diverse choice of treatment options. Younger men in good general health may be considered for primary curative therapy with surgery or radiotherapy, whereas older patients with a poorer performance status and shorter life expectancy may be suitable for active surveillance or watchful waiting ( Figure 1 ). Curative therapy is not an option for men presenting with locally advanced or metastatic disease and hormonal therapy involving medical or surgical castration is the standard approach. The ongoing increases in life expectancy, coupled with early detection, predict that the effective management of prostate cancer will become an increasingly important issue for larger numbers of men and may have significant cost implications for health providers.
Prostate cancer progresses from its initial subclinical manifestation through localized and locally advanced stages to metastatic disease by a process that is effectively driven by androgen stimulation. Androgen ablation can be achieved by medical or surgical castration, which prevents direct testosterone production, and provides a response in approximately 80% of cases. 2 The median duration of primary hormone therapy is around 16-18 months. 3, 4 Second-line hormone therapies include the addition of an anti-androgen to give complete androgen blockade (CAB), with a further effect from subsequent withdrawal, diethylstilbestrol and corticosteroids. With CAB, the addition of an anti-androgen blocks the activity of the androgens produced by peripheral tissues, but has only a limited effect on disease progression. 2 There is laboratory evidence that diethylstilbestrol may be active against hormone-refractory cells 5 and this agent is frequently used in this setting. Subsequent withdrawal of anti-androgens from CAB can elicit a short-lived response (approximately 4 months) in around 25% of patients. 5 Most, if not all, patients eventually develop hormone-refractory prostate cancer (HRPC) and until recently, at this point would expect a median survival period in the order of 12 months. [6] [7] [8] [9] In addition to a decrease in life expectancy, the development of HRPC is often associated with progressive bone metastases, substantial comorbidity, pain and decreased physical function. The treatment options at this point are essentially palliative and recent years have seen the development of new strategies. Bisphosphonates and radiotherapy are being explored in conjunction with more traditional palliative measures to control symptoms and improve both the quality and the duration of life. Historically, chemotherapy has been regarded as ineffective in the management of HRPC, with a review of clinical trials carried out between 1987 and 1991 reporting an overall response rate of only 8.7%. 10 Since then, the widespread adoption of mitoxantrone into chemotherapy regimens has been shown to reduce pain, improve quality of life measures and reduce prostate-specific antigen (PSA) levels in patients with HRPC. 11 The role of chemotherapy in the treatment of HRPC is becoming increasingly established and the inclusion of taxanes to chemotherapy regimens has been shown to provide improved symptom control and increased median survival compared with mitoxantrone. 12, 13 The initial manifestation of HRPC is a rise in the serum PSA despite appropriate hormone manipulation. Although PSA as a screening test is controversial, its use as a disease marker is much less so. In general, rises in PSA will indicate a worsening of disease, and a fall in PSA the reverse. There is no good correlation between absolute PSA levels and disease, thus one patient with a rising PSA in low double figures may have severe symptoms, whereas another with PSA values in the hundreds or even thousands may be asymptomatic. Thus, PSA values must always be interpreted in the light of the underlying trend. A useful measure of severity is the PSA doubling time (PSADT). Once PSA is rising, it usually does so in an exponential manner. The doubling time is then easily estimated. Doubling times significantly less than a year, and in particular less than 6 months, usually indicate a particularly grave prognosis. PSADT has been evaluated in a range of settings, but results are reasonably consistent both in androgensensitive and androgen-resistant patients.
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Symptoms of HRPC
The majority of advanced prostate cancer patients will develop symptomatic bony metastases and may exhibit an initial good palliative response to hormonal manipulation before the inevitable loss of hormone sensitivity. During the period of progressive hormone-refractory disease, bone metastases produce the debilitating effects of diffuse bone pain, pathological fractures and spinal cord compression that are the only too familiar hallmarks of the disease. These comorbidities will have a major impact on the patients' quality of life.
Involvement of the pelvic lymph nodes can be an early and common event in the progression of prostate cancer and is often followed by spread to more distal nodes. The involvement of the nodes, and in particular those of the pelvis, may cause obstruction of the pelvic lymphatic system with concomitant oedema, often resulting in discomfort and pain.
A number of lower urinary tract symptoms can be evident at presentation or occur on local progression, and usually result from enlargement of the prostate alone, but also in some instances from accompanying tumour invasion into the surrounding tissues. Blood in the urine or semen (uncommon of course in androgen ablated patients), increased urinary frequency, incontinence and impotence are common, cause discomfort for the patient and can be a source of great distress.
The risk of spinal comorbidities in prostate cancer arises from both a reduction in bone mineral density, as a consequence of androgen ablation therapy, and by the prevalence of spinal metastases that occur in around 85% of patients. 19 Risk factors include prolonged androgen ablation and low serum 25-hydroxyvitamin D levels. 19 Initial neuropathological symptoms, such as tingling or altered gait, are common, as are indications of progressive disease such as rising levels of PSA and these, especially in conjunction with back pain, require investigation by bone scan or scintigraphy. Left unchecked, growth of the metastases can cause compression of the spinal cord leading to further pain, marrow crowding, decreased motility, neurological dysfunction such as paraesthesia, limb weakness and incontinence, and an increased risk of pathological fractures. Following paraplegia, less than 10% of patients regain the ability to walk. 20 Spinal cord compression has a significant Figure 1 Changes in systemic therapy for prostate cancer.
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Therapeutic options
Surgery for the treatment of urological complications
Obstructive uropathy is the key urological complication of advancing prostate cancer, and is associated with poor prognosis. 22 The primary tumour can cause both bladder outflow obstruction, from direct urethral pressure, and ureteric obstruction, from tumour infiltration of the trigone and periureteric tissue. It may also cause bothersome haematuria. In addition, lymph node metastases can cause supra-vesical ureteric obstruction.
Bladder outflow obstruction not only causes obstructive uropathy, but also produces symptoms that have a considerable impact on quality of life. Both can be easily palliated with urethral catheterization. More definitive treatment may be achieved surgically or with radiotherapy. Transurethral resection of the prostate (TURP) is the preferred treatment option and can be performed in this group of patients with significant improvement in urinary symptoms and low morbidity, although rates of urinary retention and incontinence are higher than in patients undergoing TURP for benign prostatic obstruction. 23 Radiotherapy is infrequently used to improve this type of obstructive uropathy, although it can improve obstructive symptoms in up to 80% of patients. 24 Radiotherapy is, however, particularly good at treating haematuria, which is less well controlled by TURP.
Supra-vesical obstruction is usually unilateral at first, and may not require treatment if asymptomatic with adequate overall renal function. However, bilateral ureteric obstruction causes life-threatening, progressive renal failure, which requires urgent attention. Effective palliation of renal failure is usually achieved by percutaneous nephrostomy, ureteric stent or a combination of both, which are procedures with low morbidity that can improve quality of life. 25 Expandable metallic ureteric stents, extra-anatomic stents and surgical diversion are alternative methods of invasive treatment. Radiotherapy can also reduce the obstruction; however, it is neither as immediate nor effective. 26 Such palliation of renal failure raises an ethical dilemma in the hormonerelapsed patient. These patients generally have a short life expectancy and their prognosis should be considered before initiating treatment, so that life is not perpetuated to allow the development of other problems, without improving the quality of useful life.
Prednisolone and other steroids
Patients who have received medical or surgical castration will still receive androgen stimulation of their prostate tumour cells as a result of androgens produced by the adrenal glands. Treatment with steroids such as hydrocortisone reduces adrenal androgen production in a subset of patients and there is an additional benefit from low-dose corticosteroid therapy in terms of improved anabolism and reduced fatigue. 27, 28 Anti-androgen therapy will inhibit the stimulation of the prostate cancer cells by competing with residual testosterone for binding to the receptor. However, whereas a randomized trial found the time to progression and survival periods for prednisone and flutamide to be equivalent, the steroid therapy significantly improved the overall quality of life and in particular, pain, fatigue, role functioning, appetite loss and gastrointestinal distress. 29 
Radiotherapy
Bone pain in patients with locally advanced or metastatic prostate cancer is invariably indicative of bone metastases and is one of the most common signs of progression or recurrence. In patients in whom metastases are limited to a few sites, single-fraction external-beam radiotherapy is an option for palliative pain control. 30, 31 Approximately 76% of patients will have effective pain relief from this approach with a median duration of around 6 months. In addition to the low cost of localized radiotherapy, the approach also has the advantage that subsequent isolated metastases may also be treated in the same way and, if necessary, the development of pain over a larger area can be treated by wide-field or hemibody radiotherapy. Although this latter approach is often accompanied by the typical side effects of radiotherapy including nausea, vomiting and diarrhoea, which may require hospitalization, this is usually avoidable with suitable anti-emetic prophylaxis, and it remains a good treatment option for the frail and elderly in whom treatment options are limited.
Radionuclides
Palliation of bone pain arising from widespread bony metastases may be effected by the intravenous administration of radionuclides that target bone metabolism, for example strontium-89, samarium-153 and phosphorous-32. Of these, strontium-89 is the most utilized providing pain relief in up to 80% of patients, and complete freedom from pain in approximately 10%, for periods that can exceed 3 months. 32, 33 The combination of strontium-89 injection and external-beam radiotherapy improved pain relief, delayed progression and enhanced some quality of life measures compared with externalbeam therapy alone. 34 However, a phase III study has suggested that in some patients, systemic strontium-89 may be inferior to local field radiotherapy in terms of survival (11 vs 7.2 months, P ¼ 0.0457). 35 The selection of patients has a significant impact on outcome and response, and duration of response to radionuclide therapy in terms of bone pain palliation is reduced in those with widespread metastatic disease or a short life expectancy. 36, 37 Consequently, the use of radionuclides appears to be optimal at an early stage in disease management. However, their efficacy is reduced or lost with repeated use, and overtreatment can also lead to irreversible pancytopenia, which can compromise any subsequent use of chemotherapy.
Bisphosphonates
The use of bisphosphonates in oncology has increased over the last decade, although their use remains the subject of controversy in prostate cancer. The bisphosphonates inhibit bone catabolism by reducing the numbers of functioning osteoclasts and have been an 
many years, and more recently have been used to manage bone metastases in breast cancer. 38 In addition, some bisphosphonates, for example zoledronic acid but interestingly not clodronate, arrest cell proliferation, induce apoptosis and inhibit the growth factor stimulation of cultured prostate cancer cells. 39 In the early 1990s, pamidronate as a single i.v. infusion was shown to reduce bone pain in 30% of patients for between 2 and 3 weeks with no tolerability issues. 40 A later report presented pooled results from two studies (INT-05 and CGP 032) in which 378 patients received placebo or pamidronate as randomized therapy for up to 27 weeks. 41 The investigators found no significant difference between pamidronate and placebo in terms of pain measurements, analgesic use, skeletal-related events or mobility. Recently a large randomized, placebo controlled study (MRC PR05) reported that clodronate improved the pain-free survival period and overall survival periods for patients with metastatic prostate cancer compared with placebo, although the benefits did not achieve statistical significance (i.e. P40.05).
42
Further, although patients in the clodronate group were significantly less likely to experience a deterioration in their performance status (HR 0.71, 95% confidence interval 0.56-0.92, P ¼ 0.008), they reported more gastrointestinal side effects, increased lactose dehydrogenase and required more trial dose modifications. In the sister trial (MRC PR04), clodronate was added to standard therapy (radiotherapy, hormone therapy or both in 490% of patients) for locally advanced, non-metastatic prostate cancer with the objectives of determining its effect on the onset of symptomatic bone metastases or disease-specific death, overall survival and toxicity. 43 Over 500 men were randomized to receive placebo or clodronate for 5 years duration and the results from 7 years of follow-up found no evidence for prevention of bone metastases or prostate cancer death (hazard ratio 1.29, 95% confidence interval 0.92-1.82, P ¼ 0.13) and no difference in overall survival (hazard ratio 1.03, 95% confidence interval 0.76-1.39, P ¼ 0.86).
The more potent bisphosphonate zoledronate has been investigated in HRPC. Zoledronate, given at a dose of 4 mg as a 5-min infusion every 3 weeks, significantly reduced the proportion of skeletal-related events by around 11% compared with placebo (P ¼ 0.021) and increased the median time to the first of such events (P ¼ 0.011). However, there was no difference between the two groups for disease progression, performance status or quality of life. A third arm in this trial received zoledronate at an initial dose of 8 mg, but this was associated with progressive renal dysfunction, which necessitated dose reduction, and the results from this patient group were difficult to interpret and not significantly different from placebo. A 9-month extension to this study in 133 patients found that 4 mg zoledronate reduced the risk of a skeletal-related event by 53% compared with placebo (hazard ratio 0.467; 95% confidence interval 0.243-0.897, P ¼ 0.022). 44, 45 In summary, the role of bisphosphonates in the adjuvant setting is uncertain although there is some evidence to support their inclusion in pain management programmes. Two current randomized trials are addressing the use of zoledronate in prostate cancer in the UK: Stampede and Trapeze (see below).
Treatment of spinal cord compression
Dexamethasone should be given as immediate therapy to alleviate oedema. Although surgery or radiotherapy may be effective for the relief of pain and neurological complications, a surgical approach is only really a viable option for spinal cord compression in patients with otherwise good performance status and well-controlled symptoms. Preliminary data indicate that by combining radiotherapy with decompressive surgical resection, patients retain the ability to walk for a significantly longer period compared with radiotherapy alone (126 vs 35 days, P ¼ 0.006) and are also more likely to maintain continence. 46 This is therefore the preferred approach if at all possible if precompression performance status was good. Prompt diagnosis and referral to a centre specializing in spinal surgery are essential if patients are to have any chance of neurological recovery.
Summary of bone metastases management
The successful management of bone metastases is a major consideration for patients with HRPC and has the potential to make a significant impact on quality of life. The early use of palliative radiotherapy, radiotherapeutics and bisphosphonates can control pain, may delay or even possibly prevent the development of significant skeletal complications and are well tolerated with few toxicity issues. Early detection and aggressive surgery with concomitant radiotherapy in cases of spinal cord compression may preserve good neurological function, and maintain an acceptable quality of life. 46 However, in late-stage disease, radiotherapy and analgesia are currently the only real options for gross spinal complications.
Chemotherapy
Mitozantrone. Given that chemotherapy is not normally used in non-metastatic or early prostate cancer, one might expect to see substantial responses to the first exposure of cytotoxic drugs in hormone-refractory patients. Historically, this has not been the case, and despite recent developments many urologists still consider HRPC to be a chemo-insensitive condition. Over the last two decades, estramustine, vinblastine, etoposide, doxorubicin and mitozantrone have all been investigated for the treatment of HRPC. The absence of a consensus on definitive end points has hampered comparative assessments of these agents and mitozantrone plus prednisone, is approved (in the USA but not in Europe) on the basis of a significant improvement in palliative end points compared with prednisone alone. 11, 47 Mitozantrone þ prednisone improved palliation (defined as a two-point decrease in a six-point pain scale without an increase in analgesic score) in 29% of patients compared with 12% in the prednisone-only arm (P ¼ 0.01), and the duration of palliation was also significantly longer (43 vs 18 weeks, Po0.0001). There was no difference in survival between the two groups, although the trial was not powered on this basis. In addition, patients in the prednisone-only group who did not show a palliative response could cross over to the combination after 6 weeks.
A retrospective follow-up study in 161 of the original patients found that 34% of the patients in the Management of hormone-refractory, prostate cancer ND James et al mitozantrone plus prednisone group achieved a PSA response (defined as a decline of X50% relative to baseline) compared with 11% in the prednisone-only group (P ¼ 0.0001). 48 Further analyses indicated that a PSA response was associated with an increased likelihood of a palliative response (P ¼ 0.001) and, in conjunction with better performance score and a high haemoglobin level, was an indicator for increased survival (Po0.001). A separate, later study compared mitozantrone with and without hydrocortisone and found similar results; the combination provided a small but significant increase in time to progression compared with steroid monotherapy (3.7 vs 2.3 months, respectively, P ¼ 0.02) but no difference in overall median survival (12.3 vs 12.6 months, respectively, P ¼ 0.77). 49 Finally, a further study found similar extensions to the progression-free period with the combination, as well as an increase in the number of patients with a PSA response, but confirmed no survival difference between mitozantrone plus prednisone and prednisone alone. 50 A follow-up study to the initial investigation by Tannock et al. 51 examined the cost implications of introducing mitozantrone for HRPC management. A detailed examination was performed of the costs incurred for 114 patients from three of the largest centres between randomization and death and included hospital admissions, outpatient visits, investigations, all therapies and palliative care. The mean total cost for a patient who received mitozantrone with prednisolone from randomization to death was 27 300 Canadian dollars, which was effectively the same as the 29 000 Canadian dollars spent on a patient in the prednisolone-only group. The major proportion of cost in both arms was in-patient admissions (53 vs 66% for the chemotherapy and steroid-only groups, respectively). This dominant role of in-patient costs is evident when the costs for an individual patient are plotted against time (Figure 2 ). This study indicates that by reducing pain and improving function, fewer admissions were required for pain control or failure to cope at home, and that this more than offset the cost of chemotherapy. Similar deferred costs have been noted in other active treatments for HRPC, for example strontium-89, where the initial costs were recovered by savings in other aspects of patient care. 53 Docetaxel. The taxanes are a relatively new class of drugs that prevent completion of the cell cycle at the G2/ M checkpoint by stabilizing the microtubule structures of the nucleus. Preclinical studies indicated that the antitumour activity of docetaxel was superior to that of mitozantrone in prostate cancer xenograft models. 54 Docetaxel or paclitaxel in combination with estramustine demonstrated a response rate of 50% in phase II studies and was moderately well tolerated. 52 In large, direct randomized comparative phase III trials, some docetaxel combinations have demonstrated increased PSA responses, progression-free survival, overall survival, improved palliation and better quality of life compared with the clearly active, standard mitozantrone combination (Table 1) . Varying the dose and administration of docetaxel affected the relative efficacy, with, for example, the 75 and 60 mg/m 2 three-weekly regimens providing a clear increase in survival, relative to mitozantrone, whereas the 30 mg/m 2 weekly schedule did not (Figure 3) . Adverse event and serious adverse event reporting increased in the docetaxel arms of both studies, 55, 56 although the degree of significance was not consistent between studies. Low numbers of treatmentrelated deaths occurred in both the docetaxel arms and mitozantrone control arms with no clear or consistent differences. Generally, the docetaxel regimens were reasonably well tolerated and the adverse event profiles were similar to those seen with other cytotoxic regimens and included grade 3 or 4 neutropenia, fatigue, alopecia, diarrhoea and stomatitis. Although such conditions are of obvious concern, they can be managed and docetaxel therefore offers the patient with HRPC tangible benefits in terms of increased quality of life and overall survival over that provided by the current standard therapy.
Future directions
In demonstrating an increase in survival and quality of life, docetaxel has demonstrated an improvement in the treatment of what was previously thought of as a chemoinsensitive disease. The challenge for the immediate future will be to consolidate these findings and maximize the potential for existing drugs in this setting. This may be achieved by manipulating the regimens already in use, exploring the efficacy of new combinations and by investigating earlier or aggressive treatment in suitable patients. For example, a modified vinca alkaloid, vinorelbine, appears to be as effective as mitozantrone in combination with steroid therapy. 57 Another new possibility is the oral platinum analogue satraplatin, which has shown encouraging activity in HRPC and is undergoing phase III evaluation in the second-line chemotherapy setting vs best supportive care. 58, 59 This trial is set to be closed in early 2006. If positive, it will further extend the indications for chemotherapy in prostate cancer and open the way to further combination therapy trials. Figure 2 Cumulative costs from the mitoxantrone economic study for an individual patient from study randomization to death. 52 The steep parts of the curve coincide with periods of in-patient care.
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The new generation of targeted anticancer drugs such as those directed against the epidermal growth factor receptors (e.g. gefitinib, cetuximab and trastuzumab) are well tolerated and have improved the treatment of certain solid human tumours like lung, breast, colorectal and head and neck. However, their use in HRPC has yet to progress past phase II and this is unlikely given that the available data suggest that the epidermal growth factor receptor family is not a viable target for the treatment of HRPC. 60 Other therapies with activity against specific targets in HRPC are being developed. For example, atrasentan is a small molecule inhibitor of the endothelin-A receptor. Blocking the binding of the natural ligand endothlin-1 prevents autocrine stimulation and inhibits several cellular processes including hormone production, mitogenesis and cell migration. 61 The endothelin autocrine loop is upregulated in HRPC, possibly as a result of androgen ablation, and clinical studies show promising results with significant effects not only on the tumour cells, but also on bone metastases. 62 Atrasentan is well tolerated and no dose limiting toxicities were seen in phase I studies. However, in common with other targeted therapies, and unlike cytotoxic therapies such as docetaxel, phase II data for atrasentan are consistent with cytostasis, leading to delays in progression rather than a reduction in tumour burden. 63 For the time being, the role of these agents remains in doubt as the results of phase III trials mature. Nonetheless, the eventual introduction of the new targeted therapies that are now in clinical development will be an important step in the management of HRPC. Although the activity of targeted therapies as monotherapy may be limited, their good tolerability means that they can be combined with established combinations with minimal impact in terms of safety. Clearly, the options for chemotherapy in the treatment of HRPC are set to increase over the coming years.
Finally, there is a growing literature on the use of cellbased or immunotherapeutic approaches to prostate cancer. In particular, a phase III trial of a dendritic cell therapy called Provenge is underway in the USA and definitive results are eagerly awaited for this study.
Forthcoming trials in the UK
The improved quality of life and overall survival seen with docetaxel may be enhanced further by introducing this drug at an earlier stage in the natural history of prostate cancer. The STAMPEDE study (www.stampede.bham.ac.uk) commenced in September 2005 and will randomize patients with advanced or metastatic prostate cancer to one of six arms containing hormone therapy only or hormone therapy plus docetaxel, zoledronate, the COX 2 inhibitor celecoxib, celecoxib and zoledronate, or Management of hormone-refractory, prostate cancer ND James et al docetaxel and zoledronate. The study design includes initial assessments of safety and failure-free survival, so that only those arms with an acceptable safety profile and potential efficacy will be followed for survival. A further four-arm, phase II pilot study, TRAPEZE, will randomize patients with HRPC to receive docetaxel and prednisolone only, or plus zoledronate, or plus strontium-89, or plus zoledronate and strontium-89. The rationale of this study is to augment the benefits seen with docetaxel and prednisolone on survival and quality of life, with the palliative effects of bone-targeting therapies. Promising activity has already been noted with docetaxel and zoledronate in a phase I study. 64 
Conclusions
The use of chemotherapy now has the potential to improve the quality of life and extend survival in patients with HRPC. Patients with a good performance status will be more suitable for chemotherapy and so it is important that patients are referred at an early point in the development of their disease. A multidisciplinary approach involving urologists, oncologists and radiologists will enable a tailored strategy that is ideally suited for the individual patient. The new targeted therapies are better tolerated than some of the older cytotoxic chemotherapy drugs and may be useful in the treatment of the elderly or patients with a poor performance status. Studies have shown that the costs of these newer, more effective treatments can be offset by the reduction in other health-care costs needed for the treatment of the terminally ill.
